Another scRNA-seq analysis showed that DNMT3A mutations defined a cytotoxic subset associated with a significantly worse prognosis of PTCL-TBX21, this result can be used to further refine pathological heterogeneity in PTCL-NOS and suggests alternative treatment strategies for this subset of tumors [230]. The gene discussed is DNMT3A; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.